Alzheimer's drug used in cognitive dysfunction syndrome clinical trialSeptember 5, 2018Ropesalazine, a drug candidate for Alzheimer's disease (AD), has shown efficacy in a pilot clinical trial conducted for dogs with cognitive dysfunction syndrome (CDS), according to the drug's manufacturer, South Korea-based GNT Pharma. There currently is no cure for CDS, a progressive neurodegenerative disorder of senior dogs characterized by altered interaction with family, disorientation, sleep/wake cycle changes, increased house soiling, and activity change. It is accompanied by nerve cell death, amyloid plaques, and neurofibrillary tangles similar to AD, leading GNT Pharma scientists to design the pilot study to investigate whether Ropesalazine would alleviate signs of CDS, as well. "The companion dogs failed to recognize their owners before the treatment," said Jae Bong Moon, DVM, head of Irion Animal Hospital in Seoul, who led the study. "It was so amazing to see the dogs that wagged their tails for their owners and cuddled up to them within eight weeks of Ropesalazine treatment. [It] appeared to cure CDS." The study was conducted on six companion dogs age 10 or older who revealed severe cognitive dysfunction according to canine cognitive dysfunction and canine dementia rating scales. Within eight weeks following daily oral administration of Ropesalazine, all six dogs returned …
SPONSORED CONTENTCanine CHF Management approved by the FDAStudies have demonstrated increased survival time for dogs with certain types of CHF. + Learn More
